Last $0.45 USD
Change Today 0.00 / 0.00%
Volume 0.0
UNISZ On Other Exchanges
Symbol
Exchange
NASDAQ GM
OTC US
Stuttgart
As of 8:10 PM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

unilife corp-cdi (UNISZ) Snapshot

Open
$0.45
Previous Close
$0.45
Day High
$0.45
Day Low
$0.45
52 Week High
03/18/14 - $0.80
52 Week Low
05/23/14 - $0.43
Market Cap
277.1M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
621.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for UNILIFE CORP-CDI (UNISZ)

Related News

No related news articles were found.

unilife corp-cdi (UNISZ) Related Businessweek News

View More BusinessWeek News

unilife corp-cdi (UNISZ) Details

Unilife Corporation designs, develops, manufactures, and commercializes injectable drug delivery systems in the United States and internationally. The company offers Unifill Syringe, a staked (fixed) retracting needle that is designed for use with liquid stable drugs; Unifill Select for use of liquid stable drug or vaccine, or a diluent to reconstitute and deliver a lyophilized drug supplied in a vial; and Unifill Assure, a finger flange and a thumb press for the intuitive self-injection of biologics. It also provides Rita disposable auto-injector that is designed to inject the prefilled dose from a single Unifill syringe; and Lisa reusable auto-injector, which automates the removal of the needle shield and enhances needle insertion and retraction, as well as EZMix dual or multi-chamber prefilled syringe for the reconstitution and delivery of injectable therapies. In addition, the company offers the Ocu-ject, a device for the delivery of microliter sized doses of drugs; and Depot-ject, a device that is designed to enable the precise placement of a drug depot into the vitreous of the eye, as well as Micro-ject, a device for optimizing the delivery of drugs with microliter doses that are unsuited to conventional device technologies. Its customers include pharmaceutical and biotechnology companies. The company is headquartered in York, Pennsylvania.

unilife corp-cdi (UNISZ) Top Compensated Officers

Chairman, Chief Executive Officer, Member of ...
Total Annual Compensation: $630.0K
President and Chief Operating Officer
Total Annual Compensation: $511.5K
Vice President of Legal Affairs
Total Annual Compensation: $321.6K
Vice President of Corporate Quality & Regulat...
Total Annual Compensation: $266.8K
Compensation as of Fiscal Year 2013.

unilife corp-cdi (UNISZ) Key Developments

Unilife Corporation Reports Cash Flows Results for the Fourth Quarter and Full Year Ended June 30, 2014

Unilife Corporation reported cash flow results for the fourth quarter and full year ended June 30, 2014. For the fourth quarter, the company reported net cash flow used in operations of $20.009 million. Investment in physical non-current assets for the quarter was at $8.77 million. Receipts from customers were at $1.14 million. During the fourth quarter of fiscal year 2014, the company invested approximately $16 million in capital expenditures and R&D above normal quarterly investments. For the full year of 2014, the company reported net cash flow used in operations of $32.99 million. Investment in physical non-current assets for the full year was at $12.15 million. Receipts from customers were at $23.74 million.

Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers; Revises Earnings Outlook for the Full Year of 2014; Provides Outlook for the Full Year of 2015

Unilife Corporation announced an acceleration of investments in manufacturing capacity, R&D, and facilities in response to increasing demand from pharmaceutical and biotechnology companies for its products and services. During the fourth quarter of fiscal year 2014, the company invested approximately $16 million in capital expenditures and R&D above normal quarterly investments. The company has revised its full year revenue guidance for fiscal year 2014 to the high end of the $12 million to $15 million range that it announced previously. For the Full year 2015, the company anticipates revenue to show strong growth over fiscal year 2014. It expects to moderate itss investment in R&D during fiscal year 2015 while keeping SG&A largely flat. The increasing revenue and decrease in R&D investment is expected to allow the company to continue narrowing its operating income loss and operating cash flow loss during fiscal year 2015. As the mix of the revenue expands beyond fees and shifts toward commercial sales, the company expects to naturally increase its investment in capital expenditure.

Unilife Mulls Acquisitions

Unilife Corporation (ASX:UNS) filed a shelf registration. Unilife anticipate that the net proceeds from our sale of any securities will be used for general corporate purposes, including working capital, acquisitions, retirement of debt and other business opportunities.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UNISZ:US $0.45 USD 0.00

UNISZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $117.17 USD +0.69
Insulet Corp $36.11 USD +0.11
Terumo Corp ¥2,618 JPY +5.00
West Pharmaceutical Services Inc $43.43 USD -0.02
Ypsomed Holding AG SFr.85.00 CHF 0.00
View Industry Companies
 

Industry Analysis

UNISZ

Industry Average

Valuation UNISZ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 173.7x
Price/Book 77.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 19.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UNILIFE CORP-CDI, please visit www.unilife.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.